FDA’s Mermaid Problem: Makena and Pharmaceutical Half-Breeds

The Makena controversy is moving to court, and likely to a very unhappy ending for KV Pharma. But FDA’s decidedly unusual communications about compounding in the midst of that controversy may have longer term implications.